Inotuzumab is intended for the treatment of adult patients with acute lymphoblastic leukaemia who have previously treated other treatments and for whom those treatments have unsuccessful.
Dosage: This medication always should be used exactly as your healthcare practitioner has told you. Your healthcare provider will determine the appropriate dose and will give you inotuzumab injection through a drip into your vein (intravenous infusion) which will run for one hour. Every inotuzumab dose needs to be administered weekly and each treatment cycle should be for 3 doses.
If you’re not responding to this drug within three cycles, you need to interrupt your treatment.
In an event of a missed or drug overdose, call your healthcare professional team as soon as possible.
Treatment Reactions: The most commonly reported side effects with besponsa may include:
- Abdominal pain
- Febrile neutropenia
- Transaminases increased
Warnings and Precautions:
- Patients need to be monitored for the liver tests, including AST, ALT, bilirubin, and alkaline phosphatase, before and after every besponsa dose.
- Patients must be closely monitored for the toxicities post-HSCT, including the symptoms of infection as well as VOD.
- Patients need to be monitored for the complete blood counts before each dose of this drug.
- Patients must be closely monitored during and for minimum one hour following the completion of infusion.
- The use of inotuzumab ozogamicin injection by pregnant women may be responsible for causing embryo-fetal harm.
- Respective females must be instructed to avoid breastfeeding while taking treatment with inotuzumab 1 mg and for 2 months following the last dose.
- Males as well as females must seek instructions about fertility preservation prior to the treatment with inotuzumab 1 mg.